Latest Breaking News On - Jeremiahb belgica - Page 7 : comparemela.com
ARTA to audit LGU compliance with online permit rules
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
Processing of AFP, PNP benefit claims devolved to regional centers
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
ARTA aims for record Doing Business score
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
BusinessWorld
May 13, 2021 | 8:03 pm
THE ANTI-RED Tape Authority (ARTA) could soon request for lifestyle checks on Food and Drug Administration (FDA) employees and officials under investigation.
The request will be made to the Presidential Anti-Corruption Commission (PACC) with whom ARTA has a partnership to align work on corruption-related complaints sent to either agency.
The red tape watchdog in a statement on Thursday said it has gathered leads on individuals who could be recommended to PACC for lifestyle checks.
“We also have some leads that we are discussing already with our investigation team,” ARTA Director General Jeremiah B. Belgica told One News on Thursday, adding that he cannot offer more details.
ARTA issues show-cause order to FDA drug center over inaction on drug applications
May 11, 2021 | 8:29 pm
THE Anti-Red Tape Authority (ARTA) issued a show-cause order to the Food and Drug Administration’s (FDA) drug testing center for alleged inaction on more than 600 drug applications.
In a statement Tuesday, ARTA confirmed that Investigation Enforcement and Litigation Director Jedrek C. Ng sent the order to the FDA’s Center for Drug Regulation and Research Director Jesusa Joyce N. Cirunay.
ARTA said the show-cause order was a result of 23 affidavits of various pharmaceutical firms that detailed the alleged delays, some involving applications filed starting 2014.